FindTrial
Sign In

Detection of auto-antibodies in the serum and blister fluid in patients diagnosed with Bullous Pemphigoid

Evaluation of Elisa BP180 and BP230 autoantibodies in blister fluid and serum in the diagnosis of bullous pemphigoid patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/06/025985
Enrollment
50
Registered
2020-06-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L120- Bullous pemphigoid

Interventions

None listed

Sponsors

K Mahadevan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All new cases of bullous pemphigoid diagnosed by clinical examination, histopathology & by direct immunofluorescence Patients in active disease can be categorized as:Active new bullous lesions

Exclusion criteria

Exclusion criteria: Patients in clinical remission & Other bullous disorders are also excluded. Bullous pemphigoid patients without tense bullae

Design outcomes

Primary

MeasureTime frame
Detection of BP180 and BP230 antibodies in the blister fluid of bullous pemphigoid patientsTimepoint: at baseline-one time—

Secondary

MeasureTime frame
Blister fluid can be used as an alternative for blood in detecting BP180 and BP230 auto-antibodies with ELISA, especially in old age patients.Timepoint: at baseline—

Countries

India

Contacts

Public ContactHarish N

PSG Institute of Medical Sciences and Research

001harish001@gmail.com9600918402

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026